Home>Stocks>Longtop Financial Technologies Limited ADR
Longtop Financial Technologies Limited ADR
-
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma
-
A Closer Look at a Trio of Cellar-Dwellers
Fairholme Fund isn't the only one struggling in 2011.
-
Fidelity and Putnam Among Fund Families Duped by Longtop
Longtop's great growth seduced some of the biggest fund names.